Hello, I'm Greg Jenna and good news, Your Dead to Me is back for a new series. Here we go. Yes, we'll explore Emperor Nero's notorious reign with Professor Marybeard and Patton Oswald. I would not want my daughter having the remote control, not alone an empire. We'll dissect the decadent life of Philippe Duke-Dor-Leon with Tom Allen. I've often tried to pretend I'm an aristocrat and being very quickly knocked down. And there'll be so much more with comedians like Olga Koch, Mike Mosniak and Rihalina. I'm excited. You're dead to me, the comedy podcast that takes history seriously. Listen first on BBC Sounds. This is the BBC. Hello, thank you for listening to this edition of Inside Health.

I hope you enjoy it.

Inside Health may have been off air for a couple of months,

but that hasn't stopped us keeping a wary eye on the headlines,

and there's been a lot in the news about breast cancer.

The story that peaked our interest was the one about women

at increased risk of the disease not being prescribed

or declining protective drugs like tamoxifen, which got us wondering, given recent advances

in this field, some of which we've covered on the program, what is the best way of working out

how likely a woman is to develop breast cancer? And given that tamoxifen, sometimes referred to as

the statin of the breast cancer world, can reduce their risk by as much as a third, why so few

women taking it? The story starts with the publication of new guidance by Nice early last year.

Inside Health's Dr Margaret McCartney.

The Nice Guidelines offered something really different for women who were considered to be at moderate or high risk of breast cancer, and that is a drug that could potentially prevent

breast cancer in some of those women. That's different from screening, which is trying to

pick up breast cancer early. So tamoxifen for breast cancer has already been

used for decades. But this is tamoxifen being used to try and stop breast cancer, so a long-established

drug but being used in a different way. And Nice makes some quite helpful distinctions between what

is normal risk, moderate risk and high risk. And they talk about the lifetime risk of breast cancer.

The chances of a woman developing a breast cancer in her lifetime usually taken to be

till the age of 90 years. So the normal risk of the population of women in this country is less

than 17%, which might be higher than a lot of women think. The moderate lifetime risks, so that's

...